Takeda(TAK) - 2024 Q4 - Annual Report

Takeda Announces New Director Assignments (Form 6-K) Takeda announces new director assignments and governance structure following its 148th Ordinary Meeting of Shareholders Board of Directors and Governance Takeda announces new director assignments effective June 26, 2024, emphasizing a 14-member board with 11 external directors and independent committee structures - Takeda's Board of Directors consists of 14 members, with a significant majority of 11 being external directors to ensure transparency and objectivity[9] - The Audit and Supervisory Committee, Nomination Committee, and Compensation Committee are all composed exclusively of external directors, including their respective chairs[9] - The new assignments were determined at the Board of Directors meeting and the Audit and Supervisory Committee meeting on June 26, 2024[21] Directors (Not Audit and Supervisory Committee Members) This section details assignments for directors not on the Audit and Supervisory Committee, including three internal and seven external directors, with Masami Iijima chairing the Board Meeting Director Assignments (Not Audit and Supervisory Committee Members) | Name | Category | Status | Role | | :--- | :--- | :--- | :--- | | Christophe Weber | Internal | Existing | Representative Director, President & Chief Executive Officer | | Milano Furuta | Internal | New | Director, Chief Financial Officer | | Andrew Plump | Internal | Existing | Director, President, Research & Development | | Masami Iijima | External | Existing | External Director, Chair of the Board Meeting | | Ian Clark | External | Existing | External Director | | Steven Gillis | External | Existing | External Director | | Emiko Higashi | External | New | External Director | | John Maraganore | External | Existing | External Director | | Michel Orsinger | External | Existing | External Director | | Miki Tsusaka | External | Existing | External Director | Directors (Audit and Supervisory Committee Members) All four members of the Audit and Supervisory Committee are external directors, reinforcing independence, with Koji Hatsukawa leading and Jean-Luc Butel newly appointed Director Assignments (Audit and Supervisory Committee Members) | Name | Category | Status | Role | | :--- | :--- | :--- | :--- | | Koji Hatsukawa | External | Existing | External Director, Head of Audit and Supervisory Committee | | Jean-Luc Butel | External | New | External Director, Audit and Supervisory Committee Member | | Yoshiaki Fujimori | External | Existing | External Director, Audit and Supervisory Committee Member | | Kimberly A. Reed | External | Existing | External Director, Audit and Supervisory Committee Member | Committee Assignments This section details the new membership of the Nomination and Compensation Committees, both exclusively composed of external directors with specific chairs - The Nomination Committee is chaired by Masami Iijima and includes five other external directors: Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel, and Yoshiaki Fujimori[11] - The Compensation Committee is chaired by Emiko Higashi and includes three other external directors: John Maraganore, Michel Orsinger, and Kimberly A. Reed[25] Company Overview and Disclaimers This section provides an overview of Takeda's R&D-driven biopharmaceutical business, along with disclaimers regarding the informational nature of the press release and forward-looking statements - Takeda is an R&D-driven biopharmaceutical company focused on core areas including: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines[25] - The report contains forward-looking statements subject to significant risks, including economic conditions, competitive pressures, regulatory decisions, clinical success uncertainty, manufacturing delays, and currency fluctuations[15] - The press release is for informational purposes only and does not constitute an offer to purchase, subscribe for, or exchange any securities in any jurisdiction[13][27]